HLB PANAGENE Co., LTD. (KOSDAQ:046210)

Market Cap	87.75B
Revenue (ttm)	13.20B
Net Income (ttm)	-1.94B
Shares Out	43.66M
EPS (ttm)	-47.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,831
Average Volume	34,588
Open	1,945.00
Previous Close	1,968.00
Day's Range	1,944.00 - 1,989.00
52-Week Range	1,665.00 - 5,340.00
Beta	0.29
RSI	45.68
Earnings Date	May 15, 2025

About HLB PANAGENE Co., LTD.

HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The co...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 63
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2024, HLB PANAGENE Co., LTD.'s revenue was 13.20 billion, an increase of 7.71% compared to the previous year's 12.25 billion. Losses were -1.94 billion, -59.63% less than in 2023.